As of June 10, 2025, Lattice Biologics Ltd (LBL.V) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Lattice Biologics Ltd's Forward P/E to Peers
To better understand Lattice Biologics Ltd's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Lattice Biologics Ltd (LBL.V) | - |
| Protalix Biotherapeutics Inc (PLX) | 4.92 |
| Phio Pharmaceuticals Corp (PHIO) | 0.63 |
Compared to its competitors, Lattice Biologics Ltd's Forward P/E is difficult to compare due to insufficient data.